DNA methylation and expression status of glutamate receptor genes in patients with oral squamous cell carcinoma

Abstract Background Oral cancer represents the third most prevalent form of malignancy in developing countries and the eight most common form of cancer in developed countries. Alcohol and tobacco users are most affected by oral cancers and 90% of them are OSCC in adult males. In some provinces in Iran such as Sistan and Baluchestan, its prevalence is higher compared to other provinces. One of the primary neurotransmitter in the central nervous system is systemic glutamate, which is a major excitatory neurotransmitter. Glutamate signaling has been involved in various non-neuronal cancer processes. The aim of this research was to highlight the association between DNA methylation of the glutamate receptor genes and their expression pattern in pathogenesis of OSCC. Materials and methods Genomic DNA was isolated from 83 OSCC paraffin-embedded tissues (mean age: 59.67 ± 16.08) and 80 normal samples (mean age: 50.15 ± 16.69). Promoter methylation status of glutamate receptors including GRM5, GRM2 and GRIA3 genes were carried out by Methylation Specific PCR technique (MSP). We also investigated the mRNA expression levels of these genes in 15 paraffin-embedded patients and healthy samples using real-time PCR techniques. Result DNA methylation analysis showed statistically significant differences in the cases in comparison with healthy controls. Our data showed that the promoters of GRM2 and GRIA3 were methylated in the cases. For GRM2 (MM: OR = 0.32; 95% CI = 0.02–3.90; p -value = .37; MU: OR = 8.0; 95% CI = 1.37–47.34; p -value = .02) and GRIA3 (MM: OR = 47.19; 95% CI = 4.61–483.0; p-value = .001; MU: OR = 1.45; 95% CI = 0.35–5.89; p-value = .6). However, methylation of GRM5 promoter was not statistically different in the cases and healthy controls, GRM5 (MM: OR = 0.9; 95% CI = 0.14–5.71; p- value = 0.9; MU: OR = 1.83; 95% CI = 0.33–10.09; p -value = .4). In addition, the evaluation of mRNA expression levels of GRM2, GRIA3 and GRM5 were remarkably different in patients and healthy controls ( p